New drugs for children and adolescents with cancer: the need for novel development pathways.
about
A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical TrialsAssessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancersEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Declining childhood and adolescent cancer mortality: great progress but still much to be done.Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agendaDemonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot studyImproving the outcome for children with cancer: Development of targeted new agents.Drug discovery in paediatric oncology: roadblocks to progress.The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemiaInnovations for phase I dose-finding designs in pediatric oncology clinical trials.Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort.Targeted approaches to childhood cancer: progress in drug discovery and development.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.Advances in emerging drugs for the treatment of neuroblastoma.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.CREB engages C/EBPδ to initiate leukemogenesis.Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.The Effect of Regulation on Pediatric Psoriasis Drug Approvals: The Challenge of the European Union Pediatric Investigation Plans.Landscape of early clinical trials for childhood and adolescence cancer in Spain
P2860
Q28084983-76A54D68-BB88-4B7D-BD98-5A0310A3F4FFQ28545217-3B92795C-BE3D-40BF-838D-EADCCC4023A0Q30234441-E7A53F40-ECFE-4490-BB2B-65974FEC5D19Q34511492-079E4B57-BB18-4058-8229-E8E5479B096DQ34851245-FFF2F4AB-7788-419A-BFC4-7579F21C6D6DQ35929346-F25A78EF-DC4D-4E1B-AFF4-B93D0796F9C8Q36238795-B25EF3E2-1FC8-4EEF-B1CE-2F0C8347F72FQ36262295-EC269A41-E8FC-4586-A65D-10321C75B7A3Q36267151-41096376-3E8C-4DC4-A582-E870854B2A18Q36757843-A54F58E8-1C2B-49FF-95BC-CBA43FE89B65Q37452768-E0D34810-6B6F-48F4-ADC1-4F85D66E5330Q38404462-559747ED-96C4-4EAF-8B91-8FD72F58334FQ38583655-139DD1FE-5126-4A40-8A29-F069A94CF8B5Q39158415-BE4BFC2C-1111-4EEB-BFBD-32C6887BB503Q47832898-155D8D6F-0D7C-4399-9880-2A12843E94F0Q47921573-BDDC4634-98A5-49C8-B605-543EBCB97A74Q52671045-6DA278D8-04B4-47F9-AD30-2E23F339B464Q52692689-EDA02208-41FC-4F0F-AA5D-48204535CC57Q54398614-C505C48E-6195-4F84-A4E1-3828F2C88557Q57906735-F18561B5-4272-4E05-BF06-52BD559011DD
P2860
New drugs for children and adolescents with cancer: the need for novel development pathways.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
New drugs for children and ado ...... or novel development pathways.
@en
New drugs for children and ado ...... or novel development pathways.
@nl
type
label
New drugs for children and ado ...... or novel development pathways.
@en
New drugs for children and ado ...... or novel development pathways.
@nl
prefLabel
New drugs for children and ado ...... or novel development pathways.
@en
New drugs for children and ado ...... or novel development pathways.
@nl
P2093
P1433
P1476
New drugs for children and ado ...... for novel development pathways
@en
P2093
C Michel Zwaan
David Ashley
Gilles Vassal
Patricia Blanc
Peter C Adamson
P304
P356
10.1016/S1470-2045(13)70013-5
P577
2013-02-20T00:00:00Z